Dactinomycin Market Report 2024

This Dactinomycin market report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The dactinomycin market size has grown steadily in recent years. It will grow from $6.58 billion in 2023 to $6.76 billion in 2024 at a compound annual growth rate (CAGR) of 2.8%. The increase observed during the historical period can be linked to the discovery and clinical development of actinomycin, advancements in pediatric oncology, continuous research efforts, and the progression of chemotherapy.

The dactinomycin market size is expected to see steady growth in the next few years. It will grow to $7.6 billion in 2028 at a compound annual growth rate (CAGR) of 3%. In the forecast period, growth is expected to stem from the incidence and prevalence of targeted cancers, market accessibility and reimbursement options, cost-effectiveness, innovative drug delivery systems, as well as improvements in healthcare access and infrastructure. Key trends during this period include personalized medicine, the introduction of new formulations, advancements in bioinformatics and data analytics, progress in biomarker discovery, and enhancements in imaging and monitoring technologies.

The increasing incidence of cancer is projected to drive growth in the dactinomycin market. Factors contributing to the rise in cancer cases include an aging population, lifestyle choices, environmental factors, and genetic predisposition. Dactinomycin plays a crucial role in cancer treatment by inhibiting DNA transcription, which disrupts the proliferation of cancer cells and helps reduce tumor growth. For instance, the World Health Organization reported in February 2024 that by 2050, more than 35 million new cancer cases are expected, representing a 77% increase from an estimated 20 million cases in 2022. Consequently, the rising cancer incidence is propelling the growth of the dactinomycin market.

The increasing prevalence of bacterial infections is expected to propel the dactinomycin market in the coming years. Bacterial infections are caused by bacteria, which are microscopic, single-celled organisms. Dactinomycin is highly effective in cancer treatment and the prevention of bacterial diseases, as it works by inhibiting the growth of cancer cells and other bacteria. For example, according to the World Health Organization, a health agency based in Switzerland, 30 countries experienced a cholera epidemic in 2022, with a case fatality rate (CFR) of 1.9% in 2021, the highest in a decade. Thus, the increasing prevalence of bacterial infections is contributing to the expansion of the dactinomycin market.

In May 2024, Empower Pharma, a US-based pharmaceutical company, acquired manufacturing assets from Eugia US LLC, a subsidiary of Aurobindo Pharma Ltd., for $52 million. This strategic acquisition aims to enhance Empower Pharma's capabilities in sterile medication manufacturing and further its growth objectives in the pharmaceutical sector, particularly in personalized medicine. Eugia US LLC specializes in manufacturing dactinomycin drug injections.

Major companies operating in the dactinomycin market are Merck KGaA, Baxter International Inc., Teva Pharmaceutical Industries Limited, Recordati Rare Diseases Inc., Zhejiang Hisun Pharmaceutical Co. Ltd., Concord Biotech Limited, Celon Laboratories Limited, Prasco LLC, Cayman Chemical Company, Santa Cruz Biotechnology Inc., Rochem International Inc., AdvaCare International, Health Biotech Limited, Neon Laboratories Ltd, X-GEN Pharmaceuticals Inc., Florencia Healthcare, SGPharma Pvt. Ltd., BOC Sciences, Manus Aktteva Biopharma LLP, Angle Bio Pharma, Enomark Healthcare Pvt. Ltd., Meitheal Pharmaceuticals Inc.

North America was the largest region in the dactinomycin market in 2023. The regions covered in the dactinomycin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the dactinomycin market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Dactinomycin is an antitumor antibiotic obtained from the bacterium Streptomyces parvulus. It functions by binding to deoxyribonucleic acid (DNA) and inhibiting ribonucleic acid (RNA) synthesis, thereby hindering cell replication. It is primarily used in chemotherapy for various cancers, such as testicular cancer and sarcomas. Its use may result in side effects, including bone marrow suppression and gastrointestinal disturbances.

Dactinomycin is available mainly in two forms injections and implants. Injections involve administering dactinomycin as a solution directly into the bloodstream, muscle, or tumor to disrupt DNA replication. Its applications include alkylating agents, hormones, and plant medicine. The primary end users are hospitals, cancer treatment centers, and research institutions.

The dactinomycin market research report is one of a series of new reports that provides dactinomycin market statistics, including dactinomycin industry global market size, regional shares, competitors with an dactinomycin market share, detailed dactinomycin market segments, market trends and opportunities, and any further data you may need to thrive in the dactinomycin industry. This dactinomycin market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The dactinomycin market consists of sales of generic versions, formulations, and dactinomycin-related combinations. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.